Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy

Cancer Treatment and Research Communications · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles